alisol-c-23-acetate has been researched along with Osteoporosis* in 1 studies
1 other study(ies) available for alisol-c-23-acetate and Osteoporosis
Article | Year |
---|---|
Anti-osteoporotic effects of alisol C 23-acetate via osteoclastogenesis inhibition.
Alismatis rhizoma (AR) is the dried rhizome of Alisma orientale (Sam.) Juz. (Alismataceae). This traditional Chinese formula is diuretic, hypoglycemic, and hypolipidemic. Alisol C 23-acetate (AC23A) from AR is anti-inflammatory and ameliorates certain metabolic diseases. However, the mechanism by which AC23A mitigates osteoporosis is unknown. The present study investigated the anti-osteoporotic effects of AC23A in vivo and in vitro. In an ovariectomized (OVX) rat model, AC23A ameliorated OVX-induced organ coefficients and trabecular bone loss. In OVX rats, AC23A treatment lowered serum TRAP5b, CTK, β-CTX, TNF-α, IL-6, and IL-1β, raised serum E2, and did not significantly change serum OCN or BALP. AC23A inhibited osteoclast formation in a rat co-culture system without affecting osteoblast activity. RANK (receptor activator of nuclear factor kappaB) signaling channels are vital osteoclastogenesis transcription elements. AC23A inhibited RANK ligand (RANKL)-induced TRAP, c-Fos, MMP9, NFATc1, and CTK expression and JNK phosphorylation. Therefore, AC23A is anti-osteoclastogenic in vitro and in vivo by inhibiting RANKL-induced osteoclast differentiation and function. Moreover, AC23A could help prevent or limit osteoclast-mediated bone diseases by inhibiting osteoclastogenesis. Topics: Alisma; Animals; Bone and Bones; Bone Density Conservation Agents; Cells, Cultured; Cholestenones; Coculture Techniques; Drugs, Chinese Herbal; Female; Osteoclasts; Osteogenesis; Osteoporosis; Ovariectomy; RANK Ligand; Rats; Rats, Sprague-Dawley; Signal Transduction; Trabecular Meshwork | 2021 |